Vasoactive Support in Asphyxiated Neonates
- 4 hours ago
- 2 min read
Evidence, uncertainty, and clinical practice
We are excited to share our latest publication:“Vasoactive support in asphyxiated neonates: Evidence, uncertainty, and clinical practice.”
Perinatal asphyxia remains a critical condition affecting approximately 3 per 1,000 live births worldwide, often leading to hypoxic-ischemic encephalopathy (HIE), multiorgan dysfunction, and significant mortality and long-term disability.
While advances such as therapeutic hypothermia have improved outcomes, many infants with severe HIE continue to experience hemodynamic instability, requiring vasoactive support.
🔬 Why this review matters
Managing cardiovascular instability in asphyxiated newborns remains one of the most challenging aspects of neonatal intensive care.
Despite widespread use of vasoactive agents such as:
Dopamine
Dobutamine
Epinephrine
Norepinephrine
Vasopressin
Milrinone
there is no clear consensus on which agent is best, and clinical practice varies significantly between centres.
This reflects a key gap in neonatal medicine:👉 limited high-quality evidence to guide treatment decisions
⚙️ A complex physiology
Following perinatal asphyxia, newborns experience profound and dynamic circulatory changes, including:
Myocardial dysfunction
Systemic hypotension
Pulmonary hypertension
Impaired cerebral perfusion
These changes are further complicated by therapeutic hypothermia, which alters drug metabolism and cardiovascular responses.
Importantly, not all infants present the same way—hemodynamic instability is heterogeneous and evolves over time.
💡 Moving beyond “one-size-fits-all”
A key message from this work is the need to move away from a blood pressure–driven approach toward a more physiology-based, phenotype-driven strategy.
Rather than asking:👉 “Which drug increases blood pressure?”
We should ask:👉 “What is the underlying hemodynamic problem?”
For example:
Low cardiac output → consider inotropes (e.g., dobutamine)
Vasoplegia → consider vasoconstrictors (e.g., norepinephrine, vasopressin)
Pulmonary hypertension → select agents that improve the SVR:PVR balance
This tailored approach aims to better match therapy to the infant’s physiology.
📊 What does the evidence show?
Across available studies:
Most data are small, observational, or preclinical
Few randomized controlled trials exist
Short-term physiological improvements do not consistently translate into improved outcomes
Long-term neurodevelopmental data are limited
As a result, current practice is still largely based on physiologic reasoning and clinical experience rather than definitive evidence.
🔍 The role of advanced monitoring
To support individualized care, there is increasing emphasis on:
Targeted neonatal echocardiography
Near-infrared spectroscopy (NIRS)
Lactate and perfusion markers
These tools allow clinicians to better understand:
Cardiac function
Systemic blood flow
Pulmonary pressures
End-organ perfusion
This multimodal approach helps guide more precise and dynamic treatment decisions.
🚀 Looking ahead
This review highlights both progress and ongoing challenges:
No single vasoactive agent is universally superior
Hemodynamic management must be individualized
There is an urgent need for well-designed clinical trials
A standardized, physiology-driven framework is needed
Ultimately, improving outcomes for infants with perinatal asphyxia will require integrating physiology, monitoring, and evidence-based therapy.
🙌 Final thoughts
Vasoactive support in asphyxiated neonates remains an area of uncertainty—but also opportunity.
By better understanding the underlying physiology and tailoring therapies accordingly, we can move toward more precise, effective, and patient-centered care.
Stay tuned as this field continues to evolve
Comments